Single-dose safety and tolerability of TAK-638 in healthy male volunteers

Trial Profile

Single-dose safety and tolerability of TAK-638 in healthy male volunteers

Completed
Phase of Trial: Phase I

Latest Information Update: 23 Aug 2012

At a glance

  • Drugs TAK 683 (Primary)
  • Indications Prostate cancer
  • Focus Adverse reactions
  • Sponsors Takeda
  • Most Recent Events

    • 23 Aug 2012 New trial record
    • 18 Jul 2012 Results published in the British Journal of Clinical Pharmacology.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top